FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766175045> ?p ?o ?g. }

• W2766175045 endingPage "595" @default.
• W2766175045 startingPage "587" @default.
• W2766175045 abstract "BACKGROUND Health‐related quality of life (HRQOL) in patients with chronic‐phase chronic myeloid leukemia (CML) is important because of the requirement for long‐term treatment. This study assessed HRQOL in bosutinib‐treated patients with Philadelphia chromosome–positive CML and resistance or intolerance to 1 (chronic‐phase second‐line [CP2L]) or more (chronic‐phase third‐line [CP3L]) tyrosine kinase inhibitors who had 264 weeks or more of follow‐up ( ClinicalTrials.gov identifier NCT00261846). METHODS Patient‐reported HRQOL was assessed with the EuroQol 5‐Dimensions Questionnaire (EQ‐5D) and the Functional Assessment of Cancer Therapy–Leukemia (FACT‐Leu). RESULTS In total, 284 and 119 patients composed the CP2L and CP3L cohorts, respectively. At treatment completion, more than 50% of the patients in the CP2L and CP3L cohorts completed the EQ‐5D and FACT‐Leu assessments. The EQ‐5D and EQ‐5D visual analog scale scores were stable in both cohorts throughout treatment. The mean FACT‐Leu scores were generally stable over time but were lower in magnitude in the CP3L cohort versus the CP2L cohort. The FACT‐Leu scale scores of a subset of patients with chronic diarrhea (CP2L, n = 101; CP3L, n = 30) were similar to the scores of the larger cohorts. Minimally important differences (MIDs) from baseline for the FACT‐Leu scale scores were observed for the following: emotional well‐being (EWB), Functional Assessment of Cancer Therapy–General (FACT‐G) Total, FACT‐Leu Total, and Functional Assessment of Cancer Therapy Trial Outcome Index (FACT‐TOI) in the CP2L cohort and FACT‐Leu Total in the CP3L cohort. Among patients with chronic diarrhea, MIDs were observed for EWB, FACT‐G Total, FACT‐Leu Total, and FACT‐TOI in the CP2L cohort and for EWB, FACT‐G Total, and FACT‐Leu Total in the CP3L cohort. CONCLUSIONS HRQOL was maintained with long‐term bosutinib treatment for patients with CP2L and CP3L CML. Cancer 2018;124:587‐95. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society . This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes." @default.
• W2766175045 created "2017-11-10" @default.
• W2766175045 creator A5013815007 @default.
• W2766175045 creator A5015140142 @default.
• W2766175045 creator A5029270472 @default.
• W2766175045 creator A5032311442 @default.
• W2766175045 creator A5036874214 @default.
• W2766175045 creator A5044355331 @default.
• W2766175045 creator A5049530860 @default.
• W2766175045 creator A5090399884 @default.
• W2766175045 creator A5090435894 @default.
• W2766175045 date "2017-10-26" @default.
• W2766175045 modified "2023-10-16" @default.
• W2766175045 title "Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy" @default.
• W2766175045 cites W1919069136 @default.
• W2766175045 cites W1965243580 @default.
• W2766175045 cites W1965429870 @default.
• W2766175045 cites W1990020715 @default.
• W2766175045 cites W1999494567 @default.
• W2766175045 cites W2027744772 @default.
• W2766175045 cites W2028959752 @default.
• W2766175045 cites W2044966465 @default.
• W2766175045 cites W2048809946 @default.
• W2766175045 cites W2057206328 @default.
• W2766175045 cites W2057718276 @default.
• W2766175045 cites W2059705970 @default.
• W2766175045 cites W2072834954 @default.
• W2766175045 cites W2080125373 @default.
• W2766175045 cites W2082269822 @default.
• W2766175045 cites W2107268345 @default.
• W2766175045 cites W2115626434 @default.
• W2766175045 cites W2123189323 @default.
• W2766175045 cites W2129382787 @default.
• W2766175045 cites W2150604072 @default.
• W2766175045 cites W2166270808 @default.
• W2766175045 cites W2333084365 @default.
• W2766175045 cites W2558018455 @default.
• W2766175045 doi "https://doi.org/10.1002/cncr.31082" @default.
• W2766175045 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5813200" @default.
• W2766175045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29072772" @default.
• W2766175045 hasPublicationYear "2017" @default.
• W2766175045 type Work @default.
• W2766175045 sameAs 2766175045 @default.
• W2766175045 citedByCount "17" @default.
• W2766175045 countsByYear W27661750452017 @default.
• W2766175045 countsByYear W27661750452018 @default.
• W2766175045 countsByYear W27661750452019 @default.
• W2766175045 countsByYear W27661750452020 @default.
• W2766175045 countsByYear W27661750452021 @default.
• W2766175045 countsByYear W27661750452022 @default.
• W2766175045 countsByYear W27661750452023 @default.
• W2766175045 crossrefType "journal-article" @default.
• W2766175045 hasAuthorship W2766175045A5013815007 @default.
• W2766175045 hasAuthorship W2766175045A5015140142 @default.
• W2766175045 hasAuthorship W2766175045A5029270472 @default.
• W2766175045 hasAuthorship W2766175045A5032311442 @default.
• W2766175045 hasAuthorship W2766175045A5036874214 @default.
• W2766175045 hasAuthorship W2766175045A5044355331 @default.
• W2766175045 hasAuthorship W2766175045A5049530860 @default.
• W2766175045 hasAuthorship W2766175045A5090399884 @default.
• W2766175045 hasAuthorship W2766175045A5090435894 @default.
• W2766175045 hasBestOaLocation W27661750451 @default.
• W2766175045 hasConcept C121608353 @default.
• W2766175045 hasConcept C126322002 @default.
• W2766175045 hasConcept C14184104 @default.
• W2766175045 hasConcept C143998085 @default.
• W2766175045 hasConcept C159110408 @default.
• W2766175045 hasConcept C1862650 @default.
• W2766175045 hasConcept C2777413986 @default.
• W2766175045 hasConcept C2777583451 @default.
• W2766175045 hasConcept C2778208673 @default.
• W2766175045 hasConcept C2778729363 @default.
• W2766175045 hasConcept C2779951463 @default.
• W2766175045 hasConcept C71924100 @default.
• W2766175045 hasConcept C72563966 @default.
• W2766175045 hasConceptScore W2766175045C121608353 @default.
• W2766175045 hasConceptScore W2766175045C126322002 @default.
• W2766175045 hasConceptScore W2766175045C14184104 @default.
• W2766175045 hasConceptScore W2766175045C143998085 @default.
• W2766175045 hasConceptScore W2766175045C159110408 @default.
• W2766175045 hasConceptScore W2766175045C1862650 @default.
• W2766175045 hasConceptScore W2766175045C2777413986 @default.
• W2766175045 hasConceptScore W2766175045C2777583451 @default.
• W2766175045 hasConceptScore W2766175045C2778208673 @default.
• W2766175045 hasConceptScore W2766175045C2778729363 @default.
• W2766175045 hasConceptScore W2766175045C2779951463 @default.
• W2766175045 hasConceptScore W2766175045C71924100 @default.
• W2766175045 hasConceptScore W2766175045C72563966 @default.
• W2766175045 hasFunder F4320307765 @default.
• W2766175045 hasIssue "3" @default.
• W2766175045 hasLocation W27661750451 @default.
• W2766175045 hasLocation W27661750452 @default.
• W2766175045 hasLocation W27661750453 @default.
• W2766175045 hasLocation W27661750454 @default.
• W2766175045 hasOpenAccess W2766175045 @default.
• W2766175045 hasPrimaryLocation W27661750451 @default.
• W2766175045 hasRelatedWork W1972280313 @default.
• W2766175045 hasRelatedWork W2008126849 @default.

• next